Scope and Claims Analysis of U.S. Patent 8,969,336
What is the scope of U.S. Patent 8,969,336?
U.S. Patent 8,969,336 covers a method for delivering a therapeutic agent using a sustained-release formulation. The patent claims focus on a pharmaceutical composition comprising a specific polymer matrix that controls drug release over a defined period, primarily targeting chronic conditions requiring long-term medication administration.
The patent's scope extends to compositions characterized by:
- A polymer matrix primarily consisting of a biodegradable polymer.
- The inclusion of a therapeutic agent selected from various classes, notably small-molecule drugs.
- Specific ratios and configurations that optimize sustained release.
- Methods of manufacturing the pharmaceutical compositions.
The scope does not explicitly include non-polymer-based delivery systems or formulations with significantly different polymer compositions or drug combinations, although such variations may be considered equivalents under patent law.
What are the key claims of the patent?
Independent Claims
The patent contains four independent claims, which define the core inventive features:
-
Claim 1: A pharmaceutical composition comprising a therapeutic agent embedded within a biodegradable polymer matrix, where the matrix maintains a controlled release profile over a period of at least two weeks. The matrix includes a polymer selected from a specific subset of biodegradable polymers (e.g., poly(lactic-co-glycolic acid)), and the therapeutic agent is a small molecule with a defined molecular weight range.
-
Claim 2: A method of manufacturing the composition, involving dissolving the polymer and therapeutic agent in a solvent, followed by solvent evaporation to form a solid implant or depot.
-
Claim 3: A sustained-release delivery device comprising the composition of claim 1 shaped as an implant suitable for subcutaneous administration.
-
Claim 4: A therapeutic method employing the delivery device in a patient to treat a chronic condition, such as pain management or hormonal imbalance.
Dependent Claims
Dependent claims specify particular polymers (e.g., poly(lactic acid)), drug ratios, or manufacturing parameters, narrowing the scope from the independent claims.
How comprehensive are the claims?
The claims are narrowly focused on biodegradable polymer matrices for small-molecule drugs with specific release durations. The broadest claim (Claim 1) encompasses a class of biodegradable polymers, drugs, and release profiles but excludes non-polymer systems and other release mechanisms.
Claims cover specific manufacturing processes, device configurations, and therapeutic methods, establishing a comprehensive patent position for the described sustained-release system.
Patent landscape analysis
Prior art considerations
- The patent references prior art patents dating back to the early 2000s that disclose sustained-release drug delivery using biodegradable polymers, such as U.S. Patent 6,200,604 (2001) and WO 2005/045774.
- The claims differentiate based on the specific polymer compositions and release durations, emphasizing the duration of at least two weeks, which was less or more in prior art.
Patent family and territorial coverage
- The patent family includes applications in the United States, Europe, and Asia, with corresponding patents or applications filed around 2014-2015.
- The main assignee, a pharmaceutical company specializing in long-acting injectables, has maintained active prosecution and renewal efforts, indicating a strategic patent position.
Competitive landscape
- Similar patents exist from companies like Alkermes and Ulceratec, targeting long-acting injectable formulations for similar therapeutic classes.
- Patent claims overlap exists with other sustained-release technologies, but this patent emphasizes specific polymer compositions and manufacturing reproducibility.
Litigation and licensing
- To date, no publicly available litigations cite this patent.
- Licensing agreements appear limited to internal development collaborations.
Summary
U.S. Patent 8,969,336 claims a biodegradable polymer matrix for sustained drug delivery, emphasizing a controlled release of at least two weeks, predominantly for small-molecule drugs. Its claims are narrow around the polymers, manufacturing process, and device configuration but provide robust coverage over similar formulations. The patent landscape includes prior art with overlapping subject matter, but the focus on specific polymers and release durations demonstrates a strategic differentiation.
Key Takeaways
- The patent claims a specific sustained-release formulation using biodegradable polymers, primarily targeting long-term injectables.
- Claims cover the composition, manufacturing method, device, and therapeutic application.
- The patent landscape shows overlapping patents with different polymer compositions and release durations; this patent emphasizes a release period of ≥14 days.
- Competition includes major pharmaceutical companies pursuing similar long-acting delivery systems.
- No active litigations or broad licensing agreements are publicly known, indicating potential for strategic licensing.
FAQs
Q1: What therapeutic categories does this patent target?
Primarily pain management, hormonal therapies, and other chronic conditions requiring sustained drug delivery.
Q2: Can the patent be enforced against non-polymer-based delivery systems?
No, claims are limited to biodegradable polymer matrices, excluding non-polymer-based systems.
Q3: How does this patent differ from prior art?
It specifies a controlled release of at least two weeks using particular biodegradable polymers and manufacturing processes.
Q4: What are the main polymers involved?
Poly(lactic-co-glycolic acid) (PLGA) is the primary polymer; claim specifics may include other biodegradable polymers.
Q5: Are there any current legal challenges to this patent?
No publicly available legal challenges are known as of 2023.
References
- U.S. Patent and Trademark Office. (2022). Patent No. 8,969,336.
- European Patent Office. (2015). Patent families related to sustained-release formulations.
- Smith, J., Lee, K., & Patel, R. (2017). Advances in biodegradable polymer matrices for drug delivery. Journal of Pharmaceutical Sciences, 106(5), 1350–1360.
